CAVU Nutrition has announced it will introduce a new product, ThymoQuin Cortisol Support, at Natural Products Expo West 2026, positioning the launch within the industry's largest gathering for natural products.
The formula includes ThymoQuin, a USP-grade black seed extract standardised to specific levels of thymoquinone and p-cymene, with low free fatty acids and significantly higher bioavailability.
Why this matters
As consumer awareness of stress physiology increases, cortisol has become a central biomarker in discussions about sleep quality, mood balance, metabolic health and resilience.
In response to increasing demand for targeted, evidence-based solutions, CAVU Nutrition is introducing ThymoQuin Cortisol Support in response to this increased demand for targeted, evidence-based solutions
The debut at Expo West highlights a significant trend in the nutraceutical sector, emphasising the importance of measurable outcomes and human clinical validation in stress-support formulations.
While adaptogens have traditionally led the category, formulators are increasingly investigating ingredients with specific physiological effects backed by data.
ThymoQuin serves as the formula's hero ingredient. Rather than functioning as a traditional adaptogen, the ingredient has been studied for its role in modulating the gut-immune axis and supporting microbiome balance, mechanisms increasingly recognised as influential in cortisol regulation.
In a controlled human clinical study, ThymoQuin demonstrated a 44% reduction in cortisol levels within three weeks.
Participants also reported improvements in perceived stress, sleep quality and mood markers, suggesting broader systemic benefits associated with cortisol balance.
"We didn't want another generic stress product," said Mike Danielson, founder of CAVU Nutrition.
ThymoQuin stood apart by the quality of the science, the standardisation and how quickly it worked. Seeing meaningful cortisol reductions in weeks gave us confidence that this was the right foundation.
ThymoQuin was developed by TriNutra with a focus on precise composition and improved bioavailability, supported by strict quality control.
According to Morris Zelkah, CEO of TriNutra, the ingredient was designed to offer a substantiated alternative to conventional black seed oils and generalised stress blends.
"The goal was to move beyond generic positioning and deliver a standardised extract supported by clinical evidence," Zelkha said.
The research indicates ThymoQuin works in a measurable and time-bound manner, which aligns with the direction many brands are moving – toward transparency and documented efficacy.